abrdn Life Sciences Investors (NYSE:HQL) Sets New 52-Week High – Should You Buy?

Shares of abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $19.63 and last traded at $19.4820, with a volume of 39963 shares trading hands. The stock had previously closed at $19.25.

abrdn Life Sciences Investors Stock Up 1.9%

The firm’s fifty day moving average is $17.67 and its two-hundred day moving average is $17.12.

Get abrdn Life Sciences Investors alerts:

abrdn Life Sciences Investors Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Thursday, May 21st will be given a $0.56 dividend. This represents a $2.24 annualized dividend and a dividend yield of 11.4%. The ex-dividend date is Thursday, May 21st.

Institutional Trading of abrdn Life Sciences Investors

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. KPP Advisory Services LLC boosted its stake in abrdn Life Sciences Investors by 5.8% in the 1st quarter. KPP Advisory Services LLC now owns 24,591 shares of the company’s stock worth $400,000 after purchasing an additional 1,354 shares during the period. Geneos Wealth Management Inc. grew its stake in abrdn Life Sciences Investors by 200.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after acquiring an additional 1,529 shares in the last quarter. NewEdge Advisors LLC grew its stake in abrdn Life Sciences Investors by 5.2% during the second quarter. NewEdge Advisors LLC now owns 34,190 shares of the company’s stock valued at $438,000 after acquiring an additional 1,690 shares in the last quarter. Uhlmann Price Securities LLC increased its holdings in abrdn Life Sciences Investors by 2.3% in the 1st quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock valued at $1,267,000 after acquiring an additional 1,719 shares during the last quarter. Finally, First Trust Advisors LP increased its holdings in abrdn Life Sciences Investors by 4.0% in the 4th quarter. First Trust Advisors LP now owns 48,770 shares of the company’s stock valued at $818,000 after acquiring an additional 1,880 shares during the last quarter. Institutional investors own 32.21% of the company’s stock.

About abrdn Life Sciences Investors

(Get Free Report)

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.

Read More

• Five stocks we like better than abrdn Life Sciences Investors
• Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
• 5 Tech Stocks to Buy on the July Pullback
• Is OpenAI’s IPO Delay a Warning for AI Investors?
• onsemi: What the Market Gets Wrong, You Can Get Right

Receive News & Ratings for abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.